EP3213076A1 - Rekombinante borreliaproteine und verfahren zur verwendung davon - Google Patents
Rekombinante borreliaproteine und verfahren zur verwendung davonInfo
- Publication number
- EP3213076A1 EP3213076A1 EP15782207.3A EP15782207A EP3213076A1 EP 3213076 A1 EP3213076 A1 EP 3213076A1 EP 15782207 A EP15782207 A EP 15782207A EP 3213076 A1 EP3213076 A1 EP 3213076A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- borrelia
- antigens
- recombinant
- proteins
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 155
- 208000016604 Lyme disease Diseases 0.000 title claims abstract description 143
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 143
- 238000000034 method Methods 0.000 title claims abstract description 37
- 241000589968 Borrelia Species 0.000 title claims description 83
- 238000002493 microarray Methods 0.000 claims abstract description 44
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 17
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 16
- 108091007433 antigens Proteins 0.000 claims description 93
- 102000036639 antigens Human genes 0.000 claims description 93
- 239000000427 antigen Substances 0.000 claims description 91
- 102000037865 fusion proteins Human genes 0.000 claims description 42
- 108020001507 fusion proteins Proteins 0.000 claims description 42
- 238000012360 testing method Methods 0.000 claims description 31
- 108700023315 OspC Proteins 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 2
- 230000012743 protein tagging Effects 0.000 claims 1
- 241000589969 Borreliella burgdorferi Species 0.000 abstract description 26
- 238000003556 assay Methods 0.000 description 28
- 230000035945 sensitivity Effects 0.000 description 27
- 239000000523 sample Substances 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 230000000890 antigenic effect Effects 0.000 description 14
- 238000003498 protein array Methods 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 13
- 238000003491 array Methods 0.000 description 12
- 108090001030 Lipoproteins Proteins 0.000 description 11
- 102000004895 Lipoproteins Human genes 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 230000004044 response Effects 0.000 description 10
- 101100135136 Borrelia burgdorferi (strain ATCC 35210 / B31 / CIP 102532 / DSM 4680) ospB gene Proteins 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 239000013638 trimer Substances 0.000 description 8
- 101150055083 ospC gene Proteins 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 6
- 101710091045 Envelope protein Proteins 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000000405 serological effect Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 206010061591 Borrelia infection Diseases 0.000 description 3
- 208000034657 Convalescence Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 101710105715 Outer surface protein B Proteins 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000589970 Spirochaetales Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 102100038910 Alpha-enolase Human genes 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 101000693440 Anaplasma phagocytophilum (strain HZ) SUMOylated effector protein AmpA Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000908522 Borreliella Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101001030080 Diplobatis ommata Major vault protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 206010062488 Erythema migrans Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 102100024521 Ficolin-2 Human genes 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 101000620359 Homo sapiens Melanocyte protein PMEL Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- 208000008551 Lyme Neuroborreliosis Diseases 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101800004062 Protein p23 Proteins 0.000 description 1
- 101000588258 Taenia solium Paramyosin Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000011312 Vector Borne disease Diseases 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108010083856 methylglyoxal synthase Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011410 subtraction method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060867P | 2014-10-07 | 2014-10-07 | |
| US201462076059P | 2014-11-06 | 2014-11-06 | |
| PCT/US2015/054303 WO2016057562A1 (en) | 2014-10-07 | 2015-10-06 | Recombinant borrelia proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP3213076A1 true EP3213076A1 (de) | 2017-09-06 |
Family
ID=54337437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP15782207.3A Withdrawn EP3213076A1 (de) | 2014-10-07 | 2015-10-06 | Rekombinante borreliaproteine und verfahren zur verwendung davon |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3213076A1 (de) |
| JP (1) | JP2017531657A (de) |
| AU (1) | AU2015328255A1 (de) |
| CA (1) | CA2963643A1 (de) |
| HK (1) | HK1244534A1 (de) |
| WO (1) | WO2016057562A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017062535A2 (en) | 2015-10-06 | 2017-04-13 | Bio-Rad Laboratories, Inc. | Borrelia immunoassays and materials therefor |
| WO2018017998A1 (en) | 2016-07-22 | 2018-01-25 | The Research Foundation For The State University Of New York | Recombinant borrelia proteins and methods of use thereof |
| US10718767B2 (en) | 2018-03-09 | 2020-07-21 | Id-Fish Technology, Inc. | Species specific antigen sequences for tick-borne relapsing fever (TBRF) and methods of use |
| US20220034880A1 (en) * | 2018-10-01 | 2022-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | High specificity and sensitivity immunosorbent diagnostic assays with simultaneous resolution of multiple antibody isotypes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8127494A (en) * | 1993-11-01 | 1995-05-23 | Associated Universities, Inc. | Chimeric proteins comprising borrelia polypeptides: uses therefor |
| US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| US6251405B1 (en) | 1995-06-07 | 2001-06-26 | Connaught Laboratories, Inc. | Immunological combination compositions and methods |
| AU5751000A (en) | 1999-06-18 | 2001-01-09 | Brook Biotechnologies, Inc. | Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans |
| PT1311682E (pt) * | 2000-08-18 | 2008-03-11 | Brookhaven Sciences Ass Llc | Construcões recombinantes de borrelia burgdorferi |
-
2015
- 2015-10-06 JP JP2017518430A patent/JP2017531657A/ja active Pending
- 2015-10-06 EP EP15782207.3A patent/EP3213076A1/de not_active Withdrawn
- 2015-10-06 CA CA2963643A patent/CA2963643A1/en not_active Abandoned
- 2015-10-06 AU AU2015328255A patent/AU2015328255A1/en not_active Abandoned
- 2015-10-06 WO PCT/US2015/054303 patent/WO2016057562A1/en active Application Filing
-
2018
- 2018-03-06 HK HK18103163.5A patent/HK1244534A1/zh unknown
Non-Patent Citations (2)
| Title |
|---|
| None * |
| See also references of WO2016057562A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017531657A (ja) | 2017-10-26 |
| CA2963643A1 (en) | 2016-04-14 |
| AU2015328255A1 (en) | 2017-04-27 |
| HK1244534A1 (zh) | 2018-08-10 |
| WO2016057562A1 (en) | 2016-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Metts et al. | Analysis of the OspE determinants involved in binding of factor H and OspE-targeting antibodies elicited during Borrelia burgdorferi infection in mice | |
| Xiong et al. | Potential serodiagnostic markers for Q fever identified in Coxiella burnetii by immunoproteomic and protein microarray approaches | |
| US10266571B2 (en) | Lyme disease vaccine | |
| US20100292096A1 (en) | Strain and species-specific borrelia protein array | |
| WO2016057562A1 (en) | Recombinant borrelia proteins and methods of use thereof | |
| Luo et al. | Protein typing of major outer membrane lipoproteins from Chinese pathogenic Leptospira spp. and characterization of their immunogenicity | |
| Oliver Jr et al. | Antibody profiling of canine IgG responses to the OspC protein of the Lyme disease spirochetes supports a multivalent approach in vaccine and diagnostic assay development | |
| Kanagavel et al. | B-cell-specific peptides of Leptospira interrogans LigA for diagnosis of patients with acute leptospirosis | |
| Xu et al. | Profiling the humoral immune response to Borrelia burgdorferi infection with protein microarrays | |
| EP2837939A1 (de) | Verfahren zum Nachweis von H.pylori-Infektionen | |
| KR20160097325A (ko) | 결핵의 개선된 생체내 또는 시험관내 세포-매개 면역학적 진단을 위한 진단 시약 | |
| US20170212114A1 (en) | Recombinant Borrelia Proteins And Methods Of Use Thereof | |
| HEIKKILÄ et al. | Cloning of the gene encoding the decorin-binding protein B (DbpB) in Borrelia burgdorferi sensu lato and characterisation of the antibody responses to DbpB in Lyme borreliosis | |
| WO2018017998A1 (en) | Recombinant borrelia proteins and methods of use thereof | |
| RU2514230C1 (ru) | Рекомбинантные химерные полипептиды, несущие эпитопы различных иммунодоминантных белков спирохет комплекса borrelia burgdorferi sensu lato, и способ серодиагностики иксодового клещевого боррелиоза | |
| US8431135B2 (en) | Polypeptides and methods for the specific detection of antibodies in patients with a borrelia infection | |
| FI112544B (fi) | Menetelmä varhais- ja myöhäisvaiheen Lymen borrelioosin diagnosoimiseksi | |
| WO2014093619A1 (en) | Methods and compositions of protein antigens for the diagnosis and treatment of leptospirosis | |
| US8283439B2 (en) | Recombinant fragments and synthetic peptides of 17-kDa polypeptide useful in detecting Bartonella henselae | |
| CN114814211A (zh) | 一种用于检测pcv3的elisa试剂盒 | |
| Ranka et al. | Analysis of Seroreactivity to Recombinant B. burgdorferi Antigens BBA65 and BBA73 | |
| Immunosorbent | Limitations of the BP26 Protein-Based | |
| Anbarasu et al. | B-Cell-Specific Peptides of Leptospira | |
| Lesseva et al. | CLONINg AND ExpRESSION OF RECOMBINANT FLAgELLAR pROTEIN FlaB FROM BorrELIa BurgDorFErI |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20170505 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1244534 Country of ref document: HK |
|
| 17Q | First examination report despatched |
Effective date: 20181121 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20190402 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1244534 Country of ref document: HK |